The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...
Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...
Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...
JM Financial forecasts Jio’s ARPU to rise 4.5% QoQ to ₹204. Bharti Airtel is expected to see 4.8% QoQ growth in India ...
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
Following the demerger of ITC Hotels from ITC Ltd, Nuvama expects an outflow of approximately $180 million due to the ...
Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...
The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".
Media companies expected to report muted Q3FY25 results with some segments showing growth, but overall performance remains ...
The Indian economy has seen a sharp slowdown, with real GDP growth falling from 8.2 per cent in FY24 to 6 per cent in the first half of FY25. The report highlights a convergence in real and nominal ...
A long-term investor mindset will help make money, focus on new products at pharma companies draws to a close, Meta’s latest shift befuddles Indian fact-checkers, and more ...